| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
188,370,000 |
| Market
Cap: |
16.70(B) |
| Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
| 52
Week Range: |
$76.22 - $99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 811 |
| Guru Rank Value : 0.9 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
3,625 |
| Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
156,079 |
229,843 |
273,203 |
611,547 |
| Total Sell Value |
$13,472,349 |
$20,340,408 |
$24,241,430 |
$58,103,504 |
| Total People Sold |
5 |
5 |
6 |
7 |
| Total Sell Transactions |
13 |
19 |
25 |
55 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2019-11-22 |
4 |
AS |
$77.60 |
$776,000 |
D/D |
(10,000) |
327,080 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2019-11-22 |
4 |
OE |
$21.51 |
$215,100 |
D/D |
10,000 |
337,080 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2019-11-11 |
4 |
A |
$75.38 |
$754 |
D/D |
10 |
327,080 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2019-11-05 |
4 |
GD |
$0.00 |
$0 |
D/D |
450 |
327,070 |
|
- |
|
| Mueller Brian |
SVP, Acting CFO |
• – – |
2019-10-31 |
4 |
A |
$62.23 |
$560 |
D/D |
9 |
13,968 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2019-10-25 |
4 |
AS |
$69.55 |
$347,750 |
D/D |
(5,000) |
327,520 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2019-10-25 |
4 |
OE |
$21.51 |
$107,550 |
D/D |
5,000 |
332,520 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2019-09-27 |
4 |
OE |
$21.51 |
$21,510 |
D/D |
1,000 |
327,520 |
|
- |
|
| Lawlis V Bryan |
Director |
– • – |
2019-09-17 |
4 |
AS |
$74.47 |
$279,263 |
D/D |
(3,750) |
23,590 |
|
- |
|
| Lawlis V Bryan |
Director |
– • – |
2019-09-17 |
4 |
OE |
$21.51 |
$80,663 |
D/D |
3,750 |
27,340 |
|
- |
|
| Heron Elaine J |
Director |
– • – |
2019-08-07 |
4 |
OE |
$63.10 |
$97,994 |
D/D |
1,553 |
47,668 |
|
- |
|
| Anderson Elizabeth M |
Director |
– • – |
2019-07-09 |
4 |
A |
$0.00 |
$0 |
D/D |
4,490 |
4,490 |
|
- |
|
| Lawlis V Bryan |
Director |
– • – |
2019-06-17 |
4 |
AS |
$81.08 |
$304,050 |
D/D |
(3,750) |
23,590 |
|
- |
|
| Lawlis V Bryan |
Director |
– • – |
2019-06-17 |
4 |
OE |
$21.51 |
$80,663 |
D/D |
3,750 |
27,340 |
|
- |
|
| Meier Richard A |
Director |
– • – |
2019-06-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
6,000 |
80,040 |
|
- |
|
| Davis George Eric |
EVP, General Counsel |
• – – |
2019-06-05 |
4 |
GD |
$0.00 |
$0 |
D/D |
300 |
71,899 |
|
- |
|
| Baffi Robert |
President, Global Mfg/Tech Ops |
• – – |
2019-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
14,160 |
107,418 |
|
- |
|
| Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
• – – |
2019-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
14,160 |
61,635 |
|
- |
|
| Pyott David E I |
Director |
– • – |
2019-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,430 |
13,640 |
|
- |
|
| Meier Richard A |
Director |
– • – |
2019-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,430 |
86,040 |
|
- |
|
| Heron Elaine J |
Director |
– • – |
2019-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,430 |
46,115 |
|
- |
|
| Lawlis V Bryan |
Director |
– • – |
2019-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,430 |
23,590 |
|
- |
|
| Lewis Alan |
Director |
– • – |
2019-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,430 |
25,590 |
|
- |
|
| Grey Michael G |
Director |
– • – |
2019-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,430 |
38,540 |
|
- |
|
| Dere Willard H |
Director |
– • – |
2019-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,430 |
13,420 |
|
- |
|
2562 Records found
|
|
Page 19 of 103 |
|
|
1.44 (1.6%) 
